Rockefeller Capital Management L.P. increased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 95.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,875 shares of the company's stock after acquiring an additional 1,402 shares during the period. Rockefeller Capital Management L.P.'s holdings in 10x Genomics were worth $81,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TXG. First Horizon Advisors Inc. boosted its position in 10x Genomics by 14,780.0% during the second quarter. First Horizon Advisors Inc. now owns 744 shares of the company's stock worth $33,000 after purchasing an additional 739 shares in the last quarter. Wipfli Financial Advisors LLC purchased a new position in shares of 10x Genomics during the 3rd quarter valued at approximately $26,000. Atlas Capital Advisors LLC grew its stake in 10x Genomics by 41.7% in the 2nd quarter. Atlas Capital Advisors LLC now owns 935 shares of the company's stock valued at $42,000 after acquiring an additional 275 shares during the period. Captrust Financial Advisors increased its holdings in 10x Genomics by 290.5% in the 1st quarter. Captrust Financial Advisors now owns 1,636 shares of the company's stock worth $124,000 after acquiring an additional 1,217 shares in the last quarter. Finally, Column Capital Advisors LLC raised its position in 10x Genomics by 59.8% during the second quarter. Column Capital Advisors LLC now owns 1,889 shares of the company's stock worth $85,000 after acquiring an additional 707 shares during the period. 74.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TXG shares. Morgan Stanley dropped their target price on shares of 10x Genomics from $70.00 to $64.00 and set an "overweight" rating on the stock in a research report on Friday, November 4th. JPMorgan Chase & Co. reduced their target price on 10x Genomics from $65.00 to $55.00 in a report on Thursday, November 3rd. Deutsche Bank Aktiengesellschaft started coverage on 10x Genomics in a research note on Tuesday, December 13th. They issued a "buy" rating and a $50.00 price target on the stock. UBS Group started coverage on 10x Genomics in a research note on Thursday. They issued a "neutral" rating and a $50.00 price objective for the company. Finally, The Goldman Sachs Group lowered their target price on shares of 10x Genomics from $35.00 to $25.00 and set a "sell" rating on the stock in a research note on Thursday, October 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $50.90.

10x Genomics Trading Down 3.8 %

Insider Activity

In other news, CEO Serge Saxonov sold 2,676 shares of 10x Genomics stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total transaction of $91,171.32. Following the sale, the chief executive officer now owns 974,926 shares of the company's stock, valued at approximately $33,215,728.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other 10x Genomics news, CFO Justin J. Mcanear sold 1,626 shares of 10x Genomics stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total transaction of $55,397.82. Following the completion of the sale, the chief financial officer now directly owns 76,764 shares in the company, valued at $2,615,349.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 2,676 shares of the business's stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total transaction of $91,171.32. Following the completion of the sale, the chief executive officer now directly owns 974,926 shares in the company, valued at $33,215,728.82. The disclosure for this sale can be found here. Insiders sold a total of 6,663 shares of company stock valued at $227,008 in the last 90 days. Company insiders own 11.08% of the company's stock.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Stories

• Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
• Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.